31.01.2017 • NewsElaine BurridgeIneosArkema

Ineos Takes Control of Oxochimie

(c) Ineos
(c) Ineos

Ineos is taking full ownership of Oxochimie, its 50:50 joint venture with French chemicals group Arkema. Financial terms were not disclosed. The divestment, which remains subject to antitrust approval, is due to be finalized in early 2017.

Oxochimie has a site in Lavéra, France, producing butanols, 2-ethylhexanol and oxoaldehydes. The chemicals are partly used as feedstock for Arkema’s acrylic esters in Europe and are also sold on the merchant market where they generate annual sales of around €40 million. Arkema said Ineos will continue to supply the French group’s acrylic esters units.

“Oxo alcohols are a core business for Ineos Oxide, both supplying the European and global markets and supporting the manufacturing of our fast-growing downstream intermediates businesses,” said Graham Beesley, CEO of Ineos Oxide, adding that the group is looking forward to growing its global market presence.

Arkema is selling the stake as part of its ongoing program to divest businesses with annual sales totalling €700 million as it refocuses on its core businesses. Last year, the Paris-based company sold its activated carbon and filter aid operations, with annual sales of some €93 million, to US group Calgon Carbon for $163 million. In 2015, Arkema divested its Sunclear plastic and aluminium sheet distribution business to BF Invest. This business had sales of about €180 million.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.